medigraphic.com

2005, Number 1

<< Back Next >>

Bioquimia 2005; 30 (1)

Pharmacological evaluation of the effects of synthetic 1-O-dodecylglycerol in a model of inflammatory angiogenesis

Sotomayor-Pérez H, Bilbao-Díaz M, González-López B, León -Álvarez JL, Merchán-González F, Mosquera-Puig T, Hernández-Balmaseda I, Garrido-Garrido G, Valdés-Rodríguez YC

Language: Spanish
References: 33
Page: 5-12
PDF size: 85.40 Kb.


ABSTRACT

Ether lipids are modifiers of biological responses, its have shown antitumoral, immunomodulator, antiinflammatory and antiangiogenic effects in different experimental models. 1-O-alkylglycerols are analogues of ether lipids, because its present the basic structure of the ethers lipids with many pharmacological properties. We evaluated the effects of 1-O-dodecylglycerol (DDG) in an inflammatory angiogenesis model of adjuvants induced granulome. DDG reduced the granulome weight and the neovascularization associated to its development. Additionally, this compound reduced the levels of total nitrites, as a measure of nitric oxide production and inhibited the activity of total phospholipase A2 in this model.


REFERENCES

  1. Folkman J. Toward an understanding of angiogenesis: Search and discovery. Perspect Biol Med 1985: 29: 10-36.

  2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 109-131.

  3. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447.

  4. Folkman J, Ingber D. Inhibition on angiogenesis. Semin Cancer Biol 1992; 3: 89-96.

  5. Folkman J. Clinical applications of research on angiogenesis. Seminars in Medicine of the Beth Israel Hospital, Boston. N Engl J Med 1995; 333: 1157-1763.

  6. Roitt I, Brostoff J, Male D. Immunology. Chapter 5. Fifth Edition. London, UK: Mosby International Ltd. 1998: 68-70.

  7. Jackson JR, Bolognese B, Hilleass L, Kassis S, Adams J, Griswold DE. Winkler JD, Pharmacological effects of SB220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998; 284: 687-692.

  8. Jackson JR, Bolognese B, Mangar CA, Hubbard WC, Marshall LA, Winkler JD. The role of platelet activating factor and other mediators in inflammatory angiogenesis. Biochem Biophys Acta 1998; 1392: 145-152.

  9. Kobayashi S, Inaba K, Kimura I, Kimura M. Inhibitory effects of tetrandine on angiogenesis in adjuvant-induced chronic inflammation and tube formation of vascular endothelial cells. Biol Pharm Bull 1998; 21: 346-349.

  10. Berdel WE, Andreesen R, Munder PG. Synthetic alkylphospholipid analogues: a new class of antitumors agents. In: Kuo JF (Ed) Phospholipids and cellular regulation. Vol. II. Florida: CRC Press. 1985: 41-73.

  11. Houlihan WJ, Lohmeyer M, Workman P, Cheon S. Phospholipid antitumor agents. Med Res Rev 1995; 15: 157-223.

  12. Candal FJ, Bosse DC, Vogler WR, Ades EW. Inhibition of induced angiogenesis in human microvascular endothelial cell line by ET-18-OCH3. Cancer Chemother Pharmacol 1994; 34: 175-178.

  13. Vogler WR. The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo. Cancer Invest 1998; 16: 549-553.

  14. Jackson JK, Burt HM, Oktaba AM, Hunter W, Scheid MP, Mouhajir F, et al. The antineoplastic ether lipid, s-phosphonate, selectively induces apoptosis in human leukemic cells and exhibits antiangiogenic and apoptotic activity on the chorioallantoic membrane of the chick embryo. Cancer Chemother Pharmacol 1998; 41: 326-332.

  15. Burford RG, Gowdey CW. Anti-Inflammatory activity of alkoxyglycerols in rats. Inter Pharmacodyn 1968; 173: 56-70.

  16. Valdés Y. Propiedades Biológicas de los AQG de origen marino. Tesis de Doctorado en Ciencias Biológicas. 1997. Facultad de Biología. Universidad de La Habana.

  17. Sotomayor H. Efectos antitumorales in vivo de los AQG del aceite de hígado de tiburón Galeocerdo cuvieris y del 1-O-hexadecilglicerol sintético. Tesis para el título de Maestro en Ciencias. Facultad de Biología. Universidad de la Habana 1999. p. 31-49.

  18. Bilbao M. Efectos antiinflamatorios de los AQG obtenidos por síntesis química. Tesis para el título de Maestro en Ciencias. 2001. IFAL, Universidad de La Habana.

  19. León J, Merchán F, Bilbao M, Nils A. Síntesis del 1-O-dodecilglicerol. Rev Cub Farm 2002; 36 (Supl Esp 1): 127-129.

  20. Sotomayor H, Primelles FA, León JL, Merchán F, Valdés Y, González B, Mosquera T. Efectos del 1-O-hexadecilglicerol y 1-O-octadecilglicerol en un modelo de angiogénesis inflamatoria. 17ma Conferencia de Química. 2002. Universidad de Oriente, Santiago de Cuba: 86-88.

  21. Granger DL, Taintor RR, Boockvar KS, Hibbs JB. Determination of nitrate and nitrite in biological samples using bacterial nitrate reductase coupled with the Griess reaction. Methods Comp Methods Enzymol 1995; 7: 78-83.

  22. Hotter G, León OS, Catafau-Roselló J. Tissular prostanoid release phospholipase A2 activity and lipid peroxidation in pancreas transplantation. Transplantation 1991; 51: 987-990.

  23. Spector T. Refinement of the Coomasie blue method of protein quantification. Anal Biochem 1978; 86: 142-146.

  24. Colville-Nash PR, Alam CAS, Appleton I, Brown JR, Seed MP, Willoughby DA. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. J Pharmacol Exp Ther 1995; 274: 1463-1472.

  25. Bilbao M, Valdés Y, León JL, Merchán F, Santana I, Peña Y. Evaluación farmacológica de la serie homóloga de los AQG en el modelo de edema inducido por carragenina. Rev Cub Farm 2002; 36 (Supl Esp 1): 114-116.

  26. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 1991; 21: 361-374.

  27. Fajardo L, Kwan H, Kowalski J, Prionas S, Allison A. Dual role of tumour necrosis factor-alpha in angiogenesis. Am J Pathol 1992; 140: 539-544.

  28. Tuder R, Flook B, Voelkel N. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798-1807.

  29. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997; 18: 4-25.

  30. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153: 381-394.

  31. Diomede L, Llamia G, D’Incalci M, Impesatory L, Algeri M, Modest EJ. Antitumor activity of synthetic ether lipids is not enhanced by pharmacological modulation of tumor lipid composition. Int J Cancer 1994; 59: 561-580.

  32. Pignol B, Chaumeron S, Coulomb H, Maisonnet T, Vandamme B, Broquet C, Mencia-Huerta JM, Braquet P. Immunomodulatory activity of two new aza alkyl phospholipid antineoplastic drugs. Anticancer Drugs 1992; 3: 599-608.

  33. Bollag W, Majewski S, Jablonska S. Cancer combination chemotherapy with retinoids: Experimental rationale. Leukemia 1994; 9: 1453-1457.




2020     |     www.medigraphic.com